7,608.59

+28.52

+0.38%

52,280.85

+510.54

+0.99%

25,517.11

+80.11

+0.31%

2,838.01

+26.16

+0.93%

4.8820

-0.0470

-0.95%

19.04

-0.38

-1.95%

3,973.40

+74.50

+1.91%

76,936.53

-917.46

-1.18%

Crude Oil Dec 26

96.63

-7.49

-7.19%

US Private Equity

10,850.63

-82.20

-0.75%

Frankfurt - Delayed Quote EUR

Zevra Therapeutics, Inc. (1GDA.F)

9.18 +0.10 (+1.10%)

As of 3:42:59 PM GMT+1. Market Open.

Loading Chart for 1GDA.F

Chart Range Bar

Interval:

In partnership with ChartIQ

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

Zevra Therapeutics to Present at Upcoming Investor Conferences

Zevra Therapeutics to Present at Upcoming Investor Conferences

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ...

Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

Mobilize your Website

View Site in Mobile | Classic

Share by: